144 Photos and videos
Make sure to save the date for the ABCARA Annual Scientific Meeting, being held at the Adelaide Convention Centre in South Australia on Friday the 28th of August 2026!
Head to the website and subscribe to the email list to keep up with news, updates and speaker announcements.
2
2
86
Our next invited speaker is Dr Johannes vom Berg! He’s a group leader at the Institute of Laboratory Animal Science, and Co-founder and CSO of InCephalo Therapeutics. His research focuses on local immunotherapy of brain tumours and tailoring biologics to this delivery route.
1
49
Welcome the next invited speaker, Dr Gregory Stein! The CEO of Curtana Pharmaceuticals with experience as a clinician and life science executive, and in diagnostics, medical devices, pharmaceuticals and biotech.
Head to our website to register for ABCARA 2026 to see our speakers.
1
24
Welcome invited speaker Eng-Siew Koh, radiation oncologist at Liverpool Cancer Therapy Centre, NSW. Her incredible expertise ranges in adult and paediatric neuro-oncology, haematological cancers, stereotactic radiotherapy, and cancer survivorship.
Head to our website to register!
21
Meet our second keynote speaker, Professor David Ashley! An internationally renowned neuro-oncologist, Prof Ashley has been the Director of the Preston Robert Tisch Brain Tumor Center, and is now returning to Australia as the CEO of the VCCC alliance and laboratory head at WEHI.
15
Head to the Hill Canberra 2025! - A huge shout-out to BTAA for organising the event and for the fearless leadership of BTAA Chair Craig Cardinal!! We truly appreciated the engagement and support of The Hon Mark Butler, Mr Andrew Wilkie MP and Prof Richard Scolyer AO.
1
1
135
ABCARA retweeted
16 Oct 2025
Thank you to Minister for Health, Hon. @Mark_Butler_MP for meeting with consumer advocates, research groups (incl. COGNO) & funders from the Australian Brain Tumour Collaborative to discuss national priorities for brain cancer trials, research & care
#BrainCancer #ClinicalTrials
1
3
2
125
ABCARA and COGNO are delighted to announce the launch of the OPAL study - a national, multi-site Phase 1 clinical trial of CT-179, a first-in-class orally bioavailable brain penetrant small molecule targeting OLIG2, a key protein associated with glioblastoma cancer stem cells.
2
6
130
Exciting news as @ABCARA_Online comes together with COGNO and @CurtanaPharma for the OPAL Clinical Trial in Glioblastoma Patients.
3
87
ABCARA 2025 proudly sponsored by @MarkHughesFdn @braincancer_AU and @MedChemExpress - without your support this group of leaders in brain cancer research would not be able to come together with the goal of finding better outcomes for brain cancer patients.
1
2
178